l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine has been researched along with levodopa in 5 studies
| Studies (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Trials (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Recent Studies (post-2010) (l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ | 1 |
| Hisaka, A; Ihara, M; Kitani, K; Nakajima, S; Sakuma, Y; Suzuki, H; Tsuchiya, Y; Yano, M | 1 |
| Hisaka, A; Kasamatsu, S; Ohtawa, M; Takenaga, N | 1 |
| Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ | 1 |
| Hisaka, A; Ihara, M; Sawasaki, Y; Takehana, H; Tomimoto, K; Tsuchiya, Y; Yano, M | 1 |
1 review(s) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and levodopa
| Article | Year |
|---|---|
Neurotoxin-related research: from the laboratory to the clinic.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri | 1992 |
4 other study(ies) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and levodopa
| Article | Year |
|---|---|
Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine.
Topics: Acylation; Animals; Buffers; Chemical Phenomena; Chemistry; Hydrogen-Ion Concentration; Hydrolysis; In Vitro Techniques; Intestinal Mucosa; Kinetics; Levodopa; Magnetic Resonance Spectroscopy; Male; Pancreas; Rats; Rats, Inbred Strains; Solutions; Temperature | 1990 |
Quantification of L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355) by high-performance liquid chromatography using o-phthalaldehyde/N-acetyl-L-cysteine derivatization.
Topics: Acetylcysteine; Animals; Biological Availability; Carbidopa; Chromatography, High Pressure Liquid; Dogs; Levodopa; Male; o-Phthalaldehyde; Prodrugs | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors | 1989 |
A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine.
Topics: Animals; Biological Availability; Carbidopa; Chromatography, High Pressure Liquid; Dogs; Levodopa; Male; Prodrugs; Rats; Rats, Inbred Strains; Tyrosine | 1989 |